Earnings Beat May Change The Case For Aurinia Pharmaceuticals Stock
RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $18
Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
Aurinia: Q3 Earnings Snapshot
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals Raises FY2026 Sales Guidance from $315.000M-$325.000M to $325.000M-$330.000M vs $330.261M Est
Aurinia Pharmaceuticals Q3 EPS $0.23 Beats $0.22 Estimate, Sales $83.699M Beat $83.691M Estimate
Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
TD Cowen Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $18
Aurinia: Lupkynis Is A Cash Cow, But Competition And Patent Risks Cap The Upside
Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company
Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?
Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain
AUPH Stock Rallies 6% After-Hours — Here’s Why
Aurinia Settles Patent Litigation with Teva
Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037
Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.